Role of enhanced half-life factor VIII and IX in the treatment of haemophilia

British Journal of Haematology

Volumn 169, Issue 6, 2015, Pages 768-776

  Mahdi, Ali J ^a   Obaji, Samya G ^a   Collins, Peter W ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Factor IX; Factor VIII; Haemophilia; Half life; Longer acting

Indexed keywords

ALBUMIN; BAY 949027; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; LONG ACTING DRUG; MACROGOL; N8 GP; N9 GP; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

BLEEDING; BLEEDING TIME; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HEMOPHILIA; HUMAN; NONHUMAN; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; DRUG MONITORING; HALF LIFE TIME; HEMOPHILIA A; HEMOPHILIA B; MEDICATION COMPLIANCE; TREATMENT OUTCOME;

DRUG MONITORING; FACTOR IX; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 84930274386     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13360     Document Type: Review

References (43)

1. Agersø, H., Stennicke, H.R., Pelzer, H., Olsen, E.N., Merricks, E.P., Defriess, N.A., Nichols, T.C. & Ezban, M. (2012) Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia, 18, 941-947.
2. Björkman, S. (2013) Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia, 19, 753-757.
3. Björkman, S., Folkesson, A. & Jönsson, S. (2009) Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years. European Journal of Clinical Pharmacology, 65, 989-998.
4. Björkman, S., Blanchette, V.S., Fischer, K., Oh, M., Spotts, G., Schroth, P., Fritsch, S., Patrone, L., Ewenstein, B.M. & Collins, P.W. (2010) Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. Journal of Thrombosis and Haemostasis, 8, 730-736.
5. Boggio, L.N., Hong, W., Wang, M., Eyster, E. & Michaels, L.E. (2014) Bleeding phenotype with various Bay 94-9027 dosing regimens: subanalyses from the Protect VIII Study. Blood (ASH Annual Meeting Abstracts), 124, 1256.
6. Carcao, M., Zak, M., Abdul Karim, F., Hanabusa, H., Kearney, S., Lu, M., Persson, P., Rangarajan, S. & Santagostino, E. (2014) Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously treated pediatric hemophilia B patients. Blood (ASH Annual Meeting Abstracts), 124, 1513.
7. Collins, P.W., Blanchette, V.S., Fischer, K., Björkman, S., Oh, M., Fritsch, S., Schroth, P., Spotts, G., Astermark, J. & Ewenstein, B. (2009) Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostasis, 7, 413-420.
8. Collins, P.W., Fischer, K., Morfini, M., Blanchette, V.S. & Björkman, S. (2011) Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia, 17, 2-10.
9. Collins, P., Young, G., Knobe, K., Abdul, K.F., Angchaisuksiri, P., Banner, C., Gürsel, T., Mahlangu, J., Matsushita, T., Mauser-Bunschoten, E., Oldenburg, J., Walsh, C.E., Negrier, C.; for the paradigm 2 Investigators. (2014) Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood, 124, 3880-3886.
10. Coyle, T.E., Reding, M.T., Lin, J.C., Michaels, L.A., Shah, A. & Powell, J. (2014) Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. Journal of Thrombosis and Haemostasis, 12, 488-496.
11. Dumont, J.A., Liu, T., Low, S.C., Zhang, X., Kamphaus, G., Sakorafas, P., Fraley, C., Drager, D., Reidy, T. & McCue, J. (2012) Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 119, 3024-3030.
12. Fischer, K., Pendu, R., van Schooten, C.J., van Dijk, K., Denis, C.V., van den Berg, H.M. & Lenting, P.J. (2009) Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE, 4, e6745.
13. Hay, C.R.M. & DiMichele, D.M. (2012) The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood, 119, 1335-1344.
14. Lencer, W.I. & Blumberg, R.S. (2005) A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends in Cell Biology, 15, 5-9.
15. Lenting, P.J., Van Schooten, C.J.M. & Denis, C.V. (2007) Clearance mechanisms of von Willebrand factor and factor VIII. Journal of Thrombosis and Haemostasis, 5, 1353-1360.
16. Lissitchkov, T., Santagostino, E., Jotov, G., Barazani-Brutman, T., Voigt, C., Moises, T., Jacobs, I.C. & Martinowitz, U. (2013) Efficacy, PK and safety results of clinical study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B. Blood, 122, 1109.
17. Mahlangu, J., Powell, J.S., Ragni, M.V., Chowdary, P., Josephson, N.C., Pabinger, I., Hanabusa, H., Gupta, N., Kulkarni, R. & Fogarty, P. (2014) Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood, 123, 317-325.
18. Manco-Johnson, M.J., Abshire, T.C., Shapiro, A.D., Riske, B., Hacker, M.R., Kilcoyne, R., Ingram, J.D., Manco-Johnson, M.L., Funk, S., Jacobson, L., Valentino, L.A., Hoots, W.K., Buchanan, G.R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G.A., Thompson, A.A., McRedmond, K., Soucie, J.M., Austin, H. & Evatt, B.L. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. The New England Journal of Medicine, 6, 535-544.
19. Mei, B., Pan, C., Jiang, H., Tjandra, H., Strauss, J., Chen, Y., Liu, T., Zhang, X., Severs, J. & Newgren, J. (2010) Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood, 116, 270-279.
20. Metzner, H.J., Weimer, T., Kronthaler, U., Lang, W. & Schulte, S. (2009) Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thrombosis and Haemostasis, 102, 634-644.
21. Negrier, C., Knobe, K., Tiede, A., Giangrande, P. & Møss, J. (2011) Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood, 118, 2695-2701.
22. Nolte, M.W., Nichols, T.C., Mueller-Coh, J., Merricks, E.P., Pragst, I., Zollner, S. & Dickneite, G. (2012) Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs. Journal of Thrombosis and Haemostasis, 10, 1591-1599.
23. Østergaard, H., Bjelke, J.R., Hansen, L., Petersen, L.C., Pedersen, A.A., Elm, T., Møller, F., Hermit, M.B., Holm, P.K. & Krogh, T.N. (2011) Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood, 118, 2333-2341.
24. Pan, J., Liu, T., Kim, J.-Y., Zhu, D., Patel, C., Cui, Z.-H., Zhang, X., Newgren, J.O., Reames, A. & Canivel, D. (2009) Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood, 114, 2802-2811.
25. Peters, R.T., Low, S.C., Kamphaus, G.D., Dumont, J.A., Amari, J.V., Lu, Q., Zarbis-Papastoitsis, G., Reidy, T.J., Merricks, E.P. & Nichols, T.C. (2010) Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood, 115, 2057-2064.
26. Peters, R.T., Toby, G., Lu, Q., Liu, T., Kulman, J.D., Low, S.C., Bitonti, A.J. & Pierce, G.F. (2013) Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. Journal of Thrombosis and Haemostasis, 11, 132-141.
27. Potts, J., Li, S., Wang, P., Kulke, S., Pierce, G.F. & Jiang, H. (2013) The bleeding tendency in relation to predicted FVIII activity levels in severe hemophilia A patients treated with recombinant factor VIII Fc fusion protein. Blood, 122, 3590.
28. Powell, J.S., Nugent, D.J., Harrison, J.A., Soni, A., Luk, A., Stass, H. & Gorina, E. (2008) Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. Journal of Thrombosis and Haemostasis, 6, 277-283.
29. Powell, J., Martinowitz, U., Windyga, J., Di Minno, G., Hellmann, A., Pabinger, I., Maas Enriquez, M., Schwartz, L. & Ingerslev, J. (2012a) Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thrombosis and Haemostasis, 108, 913-922.
30. Powell, J.S., Josephson, N.C., Quon, D., Ragni, M.V., Cheng, G., Li, E., Jiang, H., Li, L., Dumont, J.A. & Goyal, J. (2012b) Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood, 119, 3031-3037.
31. Powell, J.S., Pasi, K.J., Ragni, M.V., Ozelo, M.C., Valentino, L.A., Mahlangu, J.N., Josephson, N.C., Perry, D., Manco-Johnson, M.J. & Apte, S. (2013) Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. New England Journal of Medicine, 369, 2313-2323.
32. Powell, J., Shapiro, A., Ragni, M., Negrier, C., Windyga, J., Ozelo, M., Pasi, J., Baker, R., Potts, J. & Li, S. (2014) Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. British Journal of Haematology, 168, 113-123.
33. Santagostino, E., Negrier, C., Klamroth, R., Tiede, A., Pabinger-Fasching, I., Voigt, C., Jacobs, I. & Morfini, M. (2012) Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood, 120, 2405-2411.
34. Santagostino, E., Jacobs, I.C., Voigt, C., Feussner, A. & Limsakun, T. (2014) Santagostino pharmacokinetic results of two phase iii clinical studies of coagulation factor IX (recombinant) albumin fusion protein (rIX-FP) in previously treated patients with hemophilia B (PROLONG 9FP). Blood (ASH Annual Meeting Abstracts), 124, 1491.
35. Shapiro, A.D. (2013) Long-lasting recombinant factor VIII proteins for hemophilia A. ASH Education Program Book, 2013, 37-43.
36. Shapiro, A.D., Ragni, M.V., Valentino, L.A., Key, N.S., Josephson, N.C., Powell, J.S., Cheng, G., Thompson, A.R., Goyal, J. & Tubridy, K.L. (2012) Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood, 119, 666-672.
37. Shapiro, A., Potts, J., Li, S., Valentino, L.A., Diao, L., Wang, P., Robinson, B., Pierce, G.F. & Jiang, H. (2013) Association of bleeding tendency with time under target FIX activity levels in severe hemophilia B patients treated with recombinant factor IX Fc fusion protein. Blood, 122, 2349.
38. Stennicke, H.R., Kjalke, M., Karpf, D.M., Balling, K.W., Johansen, P.B., Elm, T., Øvlisen, K., Möller, F., Holmberg, H.L. & Gudme, C.N. (2013) A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood, 121, 2108-2116.
39. Tiede, A., Brand, B., Fischer, R., Kavakli, K., Lentz, S.R., Matsushita, T., Rea, C., Knobe, K. & Viuff, D. (2013) Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. Journal of Thrombosis and Haemostasis, 11, 670-678.
40. Turecek, P.L., Bossard, M.J., Graninger, M., Gritsch, H., Höllriegl, W., Kaliwoda, M., Matthiessen, P., Mitterer, A., Muchitsch, E.M. & Purtscher, M. (2011) BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie, 32, S29-S38.
41. Valentino, L.A., Cong, L., Enockson, C., Song, X., Scheiflinger, F., Muchitsch, E.M., Turecek, P.L. & Hakobyan, N. (2015) The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule. Haemophilia, 21, 56-63.
42. Young, G., Mahlangu, J.N., Kulkarni, R., Nolan, B., Liesner, R., Pasi, J., Barnes, C., Neelakantan, S., Gambino, G., Cristiano, L.M., Barnowski, C., Pierce, G. & Allen, G.A. (2014a) Safety, efficacy and pharmacokinetics of recombinant factor VIII Fc fusion protein (rFVIIIFc) in previously-treated children with severe hemophilia A (Kids-ALONG). Blood (ASH Annual Meeting Abstracts), 124, 1494.
43. Young, G., Collins, P.W., Tehranchi, R., Chuansumrit, A., Hanabusa, H., Lentz, S.R., Mahlangu, J.N., Mauser-Bunschoten, E., Negrier, C., Oldenburg, J., Patiroglu, T., Santagostino, E., Zak, M. & Abdul Karim, F. (2014b) Safety and efficacy of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in previously-treated patients with hemophilia B: results from an extension trial. Blood (ASH Annual Meeting Abstracts), 124, 2846.